CLINICAL TRIALS PROFILE FOR TRIFAROTENE
✉ Email this page to a colleague
All Clinical Trials for trifarotene
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02189629 ↗ | CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-02-23 | Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris. |
| NCT02556788 ↗ | Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-11-01 | Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris. |
| NCT02566369 ↗ | Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-11-30 | Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris. |
| NCT03738800 ↗ | A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis | Terminated | Mayne Pharma International Pty Ltd | Phase 2 | 2019-05-01 | This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale. |
| NCT03915860 ↗ | Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2019-04-08 | Subject Reported Outcomes with use of Trifarotene 50 μg/g Cream in Subjects with Moderate Facial and Truncal Acne Vulgaris |
| NCT04451330 ↗ | A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) | Completed | Galderma R&D | Phase 4 | 2020-07-28 | The purpose of this study is to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV. |
| NCT04856904 ↗ | Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation | Recruiting | Galderma R&D | Phase 4 | 2021-05-28 | The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for trifarotene
Condition Name
Clinical Trial Locations for trifarotene
Trials by Country
Clinical Trial Progress for trifarotene
Clinical Trial Phase
Clinical Trial Sponsors for trifarotene
Sponsor Name
